Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FTH
STRONG SELLFaeth Therapeutics, Inc. · Healthcare · United States · $512M · Avg Vol: $1M/d
14
StockRankQ
33
V
40
M
25
P/E (TTM)
—
ROE
-113.4%
D/E
0.1x
Dividend %
—
Loading...
PRICE (1Y)-0.9%
SMA 50SMA 200
Close
$23.19
RSI (14)
57.4
52W High
$36.76
From 52W High
0.6%
SCORE BREAKDOWN
Quality
33
ROIC
-112.9%4.6
ROE
-113.4%7.1
GP/Assets
—N/A
Op. Margin
0.0%40.3
FCF/Assets
-402.7%0.2
Piotroski
238.9
Int. Cover
-50.0x6.0
D/E Ratio
0.08x69.0
Current Ratio
14.39x92.3
Value
40
P/E (TTM)
—N/A
EV/EBITDA
1.0x98.6
P/FCF
—N/A
P/B
-0.2x25.0
P/S
—N/A
Div Yield
—N/A
Momentum
25
52W High %
63%N/A
RS 6M
163%N/A
SMA 50/200
1.33xN/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$512M
P/E (Forward)
—
Gross Margin
0.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FTH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FTH | Faeth Therapeutics, Inc.(you) | $512M | 14 | STRONG SELL |
| KYTX | Kyverna Therapeutics, Inc. | $506M | 14 | STRONG SELL |
| ARVN | Arvinas, Inc. | $491M | 14 | STRONG SELL |
| EIKN | Eikon Therapeutics, Inc. | $522M | 11 | STRONG SELL |
| ASMB | Assembly Biosciences, Inc. | $490M | 18 | STRONG SELL |
| CTMX | CytomX Therapeutics, Inc. | $649M | 15 | STRONG SELL |
| ACHV | Achieve Life Sciences, Inc. | $537M | 19 | STRONG SELL |
| RZLT | Rezolute, Inc. | $497M | 19 | STRONG SELL |
| DNA | Ginkgo Bioworks Holdings, Inc. | $576M | 19 | STRONG SELL |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $628M | 11 | STRONG SELL |
Peer medians: ROE -22.7% · P/E 25.2x · Gross margin 44.3%